Prostate and other male cancers:
Indications for: XOFIGO
Treatment of patients with castration-resistant prostate cancer, symptomatic bone metastases and no known visceral metastatic disease.
See full labeling. Administer by slow IV over 1 min. 50kBq (1.35 microcurie) per kg given at 4 week intervals for 6 injections.
<18yrs: not established.
Not for use in females. Bone marrow suppression. Perform hematologic evaluation at baseline and prior to every dose. Before 1st dose, the ANC should be ≥1.5×109/L, platelets ≥100×109/L and hemoglobin ≥10g/dL. Before subsequent doses, the ANC should be ≥1×109/L and platelets ≥50×109/L; discontinue if no recovery within 6–8 weeks after last dose despite receiving supportive care. Monitor closely if evidence of compromised bone marrow reserve. Discontinue if life-threatening complications occur despite supportive care for bone marrow failure. Monitor oral intake and fluid status carefully. Embryo-fetal toxicity. Advise males (use condoms) and female partners of reproductive potential to use effective contraception during and 6 months after completion. Pregnancy. Nursing mothers: not studied.
Alpha particle-emitting radioactive therapeutic agent.
Concomitant chemotherapy: not established. Discontinue if concomitant with chemotherapy, other systemic radioisotopes or hemibody external radiotherapy.
Nausea, diarrhea, vomiting, peripheral edema, anemia, lymphocytopenia, leukopenia, thrombocytopenia, neutropenia.
Generic Drug Availability:
Single-dose vials (6mL)—1